Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics
Dose-finding clinical trial in China designed to evaluate safetyand preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in ...
Q&A: Improving liver cancer outcomes through enhanced immunotherapy
Dan G. Duda, DMD, Ph.D., of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at ...
Targeted Oncology1d
Behind the LEAP-012 Trial of Lenvatinib, Pembrolizumab, and TACE in HCC
Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment ...
Patients with MAFLD have 4.7 times higher risk of developing liver cancer, study finds
Research has revealed that in the case of metabolic dysfunction-associated fatty liver disease (MAFLD), the risk of ...
News Medical2d
Promising combination therapy could improve liver cancer outcomes
Importantly, hepatocellular carcinoma (HCC), the most common form of liver cancer, is now the fifth leading cause of cancer-related deaths in the United States and is projected to rise to the third by ...
News Medical4d
TCR sequencing sheds light on tumor immune interactions in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.
Hosted on MSN4d
Exosome-Mediated Immune Escape and Tumor Growth in Hepatocellular Carcinoma
The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of ...
EurekAlert!5d
Exosome-mediated crosstalk in the tumor immune microenvironment: Critical drivers of hepatocellular carcinoma progression
Hepatocellular carcinoma (HCC) is a significant global health issue, ranking as the sixth most prevalent malignancy and the ...
EurekAlert!3d
Research Spotlight: Improving liver cancer outcomes through enhanced immunotherapy
Dan G. Duda, DMD, PhD, of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General Hospital, is the corresponding author of a paper published in ...